1. COVID-19 in patients with multiple myeloma: a cross-sectional survey from the most severely affected region in China.
- Author
-
Sun, Chunyan, Li, Junying, Xiang, Hang, Li, Chunrui, Shang, Anfang, Chang, Wei, Gui, Xiya, Wang, Yadan, Wang, Hongxiang, Cheng, Qianwen, Zhang, Chun, Yuan, Guolin, Wan, Chucheng, Liu, Qihuan, Wang, Long, Huang, Zhiping, Liang, Caixia, Wu, Yaogong, and Hu, Yu
- Subjects
- *
COVID-19 , *MULTIPLE myeloma , *COUGH , *MONOCLONAL gammopathies - Abstract
Although several reports regarding COVID-19 among MM patients have been published at the time of writing [[6]], we still could not reach an agreement on risk co-variates and prognosis of COVID-19 in MM population. Since December 2019, when coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan and then spread worldwide, there have been several studies on SARS-CoV-2 infection in cancer patients [[1]]. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Hospital exposure to COVID-19 should be avoided and tailored chemotherapy regimens should be planned for MM patients during COVID-19 epidemic. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF